Compare Newegg Commerce Inc (NEGG) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Newegg Commerce Inc vs Novo Nordisk A/S — how do they compare? Newegg Commerce Inc trades at $14.93 (market cap $315.87M), while Novo Nordisk A/S trades at $44.91 (market cap $200.69B). The key difference: Novo Nordisk A/S is far larger — about 635.4× Newegg Commerce Inc's market cap, and Novo Nordisk A/S pays a 3.98% dividend while Newegg Commerce Inc pays none. Which is the better fit depends on your goals.
| NEGG | NVO | |
|---|---|---|
Market Cap | $315.87M | $200.69B |
Sector | Consumer Cyclical | Health |
52-Week High | $92.74 | $63.98 |
52-Week Low | $12.87 | $35.29 |
Enterprise Value | $286.10M | $215.49B |
Dividend Yield | — | 3.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NEGG trades at $15.17, down 0.98% on the day, with a bearish technical signal from moving averages but recent earnings beats showing improvement. The company reported Q2 2026 EPS of $0.11, beating expectations by $0.51, while revenue trends show stabilization after declines from 2022-2024. Valuation metrics include a P/E of 33.27 and P/S of 0.23, with improving profitability margins.
The outlook suggests cautious optimism as NEGG demonstrates operational improvement with four consecutive earnings beats and positive net income projected for 2026. Key risks include negative operating cash flow and competitive e-commerce pressures, while the single analyst coverage maintains a Buy rating with 100% consensus.
Novo Nordisk (NVO) trades at $45.16, down 3.09% today, with bearish technical signals but strong fundamentals. The stock shows robust profitability with 35.35% net margin and 59.82% ROE, supported by consistent earnings beats. Recent developments include positive pediatric obesity trial results for semaglutide and Wegovy pill launch in Germany. Cash flow remains healthy with $10.81B net inflow in 2025, though 2026 projections show a decline.
NVO presents a mixed outlook with strong fundamental metrics offset by technical weakness and competitive pressures. Investment opportunity lies in the expanding GLP-1 market and pipeline developments, while risks include market share loss to Eli Lilly and failed cardiovascular drug trials. Analyst consensus leans bullish with 57.9% buy ratings, but recent prescription slowdown concerns warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Newegg Commerce Inc
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products and provides certain third-party logistics services globally.
Read more on NEGG →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
